Search Result

Results for "

SHRs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADC Cytotoxin (1) Adrenergic Receptor (2) Amino Acid Derivatives (1) Androgen Receptor (1) Angiotensin Receptor (2) Angiotensin-converting Enzyme (ACE) (2) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (9) Calcium Channel (4) CDK (3) EGFR (5) ERK (2) GLP Receptor (1) Guanylate Cyclase (1) HBV (1) Indoleamine 2,3-Dioxygenase (IDO) (1) JAK (2) mAChR (1) NF-κB (3) Oxytocin Receptor (1) p38 MAPK (3) PARP (1) PCSK9 (1) PD-1/PD-L1 (3) PDGFR (3) Phosphodiesterase (PDE) (1) Raf (1) Reactive Oxygen Species (3) ROR (1) SGLT (1) TGF-β Receptor (1) Topoisomerase (1) VEGFR (3)
By Research Areas:	Cancer (25) Cardiovascular Disease (15) Endocrinology (2) Infection (1) Inflammation/Immunology (4) Metabolic Disease (3) Neurological Disease (8)

By Targets:

5-HT Receptor (1)

ADC Cytotoxin (1)

Adrenergic Receptor (2)

Amino Acid Derivatives (1)

Androgen Receptor (1)

Angiotensin Receptor (2)

Angiotensin-converting Enzyme (ACE) (2)

Antibody-Drug Conjugates (ADCs) (2)

Apoptosis (9)

Calcium Channel (4)

CDK (3)

EGFR (5)

ERK (2)

GLP Receptor (1)

Guanylate Cyclase (1)

HBV (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

JAK (2)

mAChR (1)

NF-κB (3)

Oxytocin Receptor (1)

p38 MAPK (3)

PARP (1)

PCSK9 (1)

PD-1/PD-L1 (3)

PDGFR (3)

Phosphodiesterase (PDE) (1)

Raf (1)

Reactive Oxygen Species (3)

ROR (1)

SGLT (1)

TGF-β Receptor (1)

Topoisomerase (1)

VEGFR (3)

By Research Areas:

Cancer (25)

Cardiovascular Disease (15)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (3)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137448

Rezvilutamide SHR3680	Androgen Receptor	Cancer
Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer .

HY-151367

SHR2415	ERK	Cancer
SHR2415 is a highly potent, selective and orally active ERK1/2 inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC₅₀ values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC₅₀ value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer .

HY-P99944

SHR-1701 Retlirafusp alfa	PD-1/PD-L1 TGF-β Receptor	Cancer
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .

HY-104065

Pyrotinib Maximum Cited Publications 15 Publications Verification SHR-1258	EGFR	Cancer
Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-104065B

Pyrotinib dimaleate Maximum Cited Publications 15 Publications Verification SHR-1258 dimaleate	EGFR	Cancer
Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-144319

SHR5133	HBV	Infection
SHR5133 is a highly potent, orally active HBV capsid assembly modulator. SHR5133 displays HBV DNA reduction (EC₅₀=26.6 nM) .

HY-164763

SHR-A1201	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .

HY-104065BR

Pyrotinib dimaleate (Standard)	EGFR	Cancer
Pyrotinib dimaleate (Standard) is the analytical standard of Pyrotinib dimaleate. This product is intended for research and analytical applications. Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-144269

SHR902275	Raf	Cancer
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC₅₀s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF ^wt, and bRAF ^V600E, respectively. SHR902275 shows cell growth inhibition with GI₅₀s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively .

HY-114338A

Dalpiciclib hydrochloride SHR-6390 hydrochloride	CDK	Cancer
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

HY-114338

Dalpiciclib SHR-6390	CDK	Cancer
Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4?nM and 9.9?nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

HY-155787

SHR5428	CDK	Cancer
SHR5428 is a potent, orally active, selective and noncovalent inhibitor of CDK7 with highly potent CDK7 enzymatic activity (IC₅₀=2.3 nM). SHR5428 inhibits triple negative breast cancer cellular activity on MDA-MB-468 cell (IC₅₀=6.6 nM) .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia .

HY-128351

SHR1653	Oxytocin Receptor	Neurological Disease Endocrinology
SHR1653 is a highly potent, selective and brain penetrated oxytocin receptor (OTR) antagonist, with an IC₅₀ of 15 nM for hOTR .

HY-115879

SHR168442	ROR	Inflammation/Immunology Cancer
SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC₅₀ value of 0.035 μM.

HY-128355A

(R)-IDO/TDO-IN-1	Indoleamine 2,3-Dioxygenase (IDO)	Others Cancer
(R)-IDO/TDO-IN-1 (compound 25) is an indoleamine-2,3-dioxygenase (IDO) inhibitor, with good pharmacokinetic properties. (R)-IDO/TDO-IN-1 exhibits anti-tumor activity in MC38 xenograft model. (R)-IDO/TDO-IN-1 shows synergistic effect with anti-PD-1 monoclonal antibody (SHR-1210) .

HY-104065A

(Rac)-Pyrotinib (Rac)-SHR-1258	Others	Cancer
(Rac)-Pyrotinib ((Rac)-SHR-1258) is the racemate of Pyrotinib (HY-104065). Pyrotinib is a potent and selective EGFR/HER2 dual inhibitor.

HY-107322A

Barnidipine Mepirodipine; YM-09730-5 Free base	Calcium Channel	Cardiovascular Disease
Barnidipine (Mepirodipine) is an L-type calcium antagonist (CaA) with high affinity for [ ³H] initrendipine binding sites (K_i = 0.21 nmol/L), has selective action against CaA receptors. Barnidipine is an orally effective antihypertensive agent that can reduce the level of platelet-derived growth factor B-chain mRNA and peripheral vascular resistance .

HY-116262

SCH 51866	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
SCH 51866 is a potent, selective and orally active inhibitor of PDE1 (IC₅₀=70 nM) and PDE5 (IC₅₀=60 nM). SCH 51866 inhibits collagen-induced aggregation of human washed platelets (IC₅₀=10 μM), prevents neointimal formation in balloon catheter-injured carotid arteries of spontaneously hypertensive rats (SHR), and reduces blood pressure in SHR. SCH 51866 can be used in the study of hypertension .

HY-155042

Antihypertensive agent 3	Angiotensin Receptor	Cardiovascular Disease
Antihypertensive agent 3 (compound 4a) is an antagonis of angiotensin II receptor 1. Antihypertensive agent 3 exhibits antihypertensive activity in a spontaneously hypertensive rats (SHRs) model .

HY-B1388

Homatropine methylbromide Homatropine methobromide	mAChR	Neurological Disease
Homatropine methylbromide (Homatropine methobromide) is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC₅₀ of 162.5 nM and 170.3 nM, respectively.

HY-153350

ERK-IN-7	ERK	Cancer
ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively .

HY-121550

ME3221	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
ME3221 is an angiotensin AT1 receptor antagonist that effectively antagonizes the pressor response to angiotensin II in rats and marmosets without affecting the hypotensive response to bradykinin. It demonstrates potent antihypertensive effects in renal hypertensive rats and spontaneously hypertensive rats (SHR), with efficacy comparable to or better than losartan in vivo. ME3221's repeated administration in SHR results in sustained and stable hypotensive effects without affecting heart rate, indicating its potential for treating both renal and essential hypertension similarly to losartan .

HY-P9971

Camrelizumab 3 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-147408

Rezetecán SHR9265	Topoisomerase ADC Cytotoxin	Cancer
Rezetecán (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecán can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-136630

Felotaxel SHR110008	Others	Others
Felotaxel (SHR110008) is a compound with antitumor activity that has specific pharmacokinetic properties in rats and is rapidly distributed to normal tissues. The kidney is the major excretion organ, and its plasma protein binding capacity is nearly linearly related to concentration.

HY-123011

Henagliflozin SHR3824	SGLT	Metabolic Disease
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC₅₀ values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .

HY-136625

LY134046	Others	Neurological Disease
LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT). Its cardiovascular activity was studied in anesthetized spontaneously hypertensive rats (SHR). Acute intraperitoneal injection of 10 and 20 mg/kg of LY134046 caused minimal cardiovascular changes, while 40 mg/kg resulted in a sustained decrease in mean arterial blood pressure and heart rate. This hypotension and bradycardia occurred rapidly and occurred when brain NMT activity was significantly inhibited. However, norepinephrine concentrations in rat brains were not significantly reduced at the time when LY134046-induced blood pressure and heart rate effects were maximal. The acute cardiovascular activity of LY134046 was not significantly affected by pretreatment of SHR with phentolamine, propranolol, or atropine, and LY134046 reduced heart rate in suspended SHR. In addition, acute or chronic administration of LY134046 did not antagonize the vasoconstrictor responses induced by sympathetic nerve stimulation or exogenous norepinephrine. These observations suggest that LY134046 does not interact with adrenergic or cholinergic receptors and that its hypotensive and bradycardic effects do not require neurogenic tension. Chronic intraperitoneal administration of LY134046 (40 mg/kg/day) resulted in a sustained and significant inhibition of hypothalamic and brainstem NMT activity, leading to central norepinephrine depletion. During chronic treatment, norepinephrine and dopamine concentrations increased in the brainstem and hypothalamus of SHR. Despite chronic inhibition of central NMT and norepinephrine depletion, cardiovascular parameters in SHR treated groups were not significantly different from those in saline-injected controls. Chronic treatment with LY134046 did not result in tolerance to its central biochemical effects or acute cardiovascular activity. The present study does not support the idea that norepinephrine-producing neurons are involved in the central regulation of cardiovascular function, because the hypotension and bradycardia induced by acute administration of LY134046 occurred before a significant decrease in hypothalamic norepinephrine concentrations, whereas chronic inhibition of central NMT and depletion of norepinephrine resulted in minimal changes in baseline cardiovascular parameters.

HY-107398

1-(2,3-Dichlorophenyl)ethanamine hydrochloride	Others	Cardiovascular Disease
1-(2,3-Dichlorophenyl)ethanamine hydrochloride is a phenylethanolamine N-methyltransferase (PNMT) inhibitor. 1-(2,3-Dichlorophenyl)ethanamine hydrochloride effectively reduces blood pressure of spontaneously hypertensive. 1-(2,3-Dichlorophenyl)ethanamine hydrochloride can be used for the research of blood pressure .

HY-P4296

H-Gly-Sar-Sar-OH	Amino Acid Derivatives	Others
H-Gly-Sar-Sar-OH is an orally active tripeptide. H-Gly-Sar-Sar-OH is transported through PepT1 within Caco-2 cells. H-Gly Sar Sar OH has potential applications in material transportation .

HY-108713

Famitinib SHR1020	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .

HY-A0117

Temocaprilat Temocapril diacid; Temocaprilate; RS 5139	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocaprilat (Temocapril diacid) is an inhibitor of angiotensin-converting enzyme (ACE). Temocaprilat alleviates the inhibitory effect of high glucose on the proliferation of aortic endothelial cells. Temocaprilat has potential applications in hypertension and vascular inflammation .

HY-116680

LY53857	5-HT Receptor	Cardiovascular Disease Neurological Disease
LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT₂ receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .

HY-108713A

Famitinib malate SHR1020 malate	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer .

HY-108713R

Famitinib (Standard)	VEGFR PDGFR Apoptosis	Cancer
Famitinib (Standard) is the analytical standard of Famitinib. This product is intended for research and analytical applications. Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .

HY-112724

Ivarmacitinib SHR0302	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-106720

Amosulalol YM 09538	Adrenergic Receptor	Cardiovascular Disease
Amosulalol (YM 09538) is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR) .

HY-112724A

Ivarmacitinib sulfate SHR0302 sulfate	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) sulfate is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-106720A

Amosulalol hydrochloride YM 09538 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Amosulalol (YM 09538) hydrochloride is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol hydrochloride exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol hydrochloride decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR) .

HY-164762

Trastuzumab rezetecan SHR-A1811	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-N9113

1,3,5,6-Tetrahydroxyxanthone	Others	Cardiovascular Disease
1,3,5,6-Tetrahydroxyxanthone is a natural xanthone that can be isolated from Garcinia achachairu Rusby (Clusiaceae) branches. 1,3,5,6-Tetrahydroxyxanthone induces diuresis and saluresis in normotensive and hypertensive rats .

HY-114778

Fluzoparib 1 Publications Verification SHR3162; Fuzuloparib	PARP	Cancer
Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC₅₀=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .

HY-153369

BAY-747	Guanylate Cyclase	Cardiovascular Disease Neurological Disease
BAY-747 is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .

HY-139792

Besigliptin tosylate SHR117887	Others	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

HY-B0612

Lercanidipine 1 Publications Verification	Calcium Channel Apoptosis Reactive Oxygen Species p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease
Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .

HY-B0612A

Lercanidipine hydrochloride 1 Publications Verification	Calcium Channel Apoptosis Reactive Oxygen Species p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease
Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .

HY-B0612AR

Lercanidipine hydrochloride (Standard)	Calcium Channel Apoptosis Reactive Oxygen Species p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease
Lercanidipine (hydrochloride) (Standard) is the analytical standard of Lercanidipine (hydrochloride). This product is intended for research and analytical applications. Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .

HY-103247

EMD 66684	Angiotensin Receptor	Cardiovascular Disease
EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC₅₀ value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant ^- .

Cat. No.	Product Name	Target	Research Area